• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Diabetes, Hypertension, Heart Disease Top Black Americans’ Clinical Research Priorities

Diabetes, Hypertension, Heart Disease Top Black Americans’ Clinical Research Priorities

April 26, 2021

A recent poll by the Pharmaceutical Research and Manufacturers of America (PhRMA) finds diabetes, hypertension and heart disease atop a list of diseases seen as a clinical research priority for Black Americans.

Of the 253 Black Americans asked to rate the importance of conducting clinical research on six diseases or conditions that affect their racial group, 19 percent said diabetes should be the top focus of clinical trials. Hypertension and heart disease both received 15 percent, while 14 percent named cancer. Blood pressure was selected by 10 percent, and 5 percent said asthma.

When asked to name the most important benefits of racially diverse clinical trials, 35 percent said diversity would help ensure approved medications are equally safe and effective for Black and nonBlack populations. Supporting the overall quality of and community access to healthcare for Black Americans was the second choice at 26 percent. Identifying the most effective ways to prevent diseases that disproportionately affect Black Americans was third at 15 percent.

Only 11 percent said shifting the U.S. healthcare system’s priorities and understanding how genetics, heredity and racial differences impact care was the most important benefit of more diverse trials, and 6 percent named supporting needed changes in practice and building a more just, equitable society.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing